종근당

185750KOSPI의약품 제조업

50.4 / 100

Reference Date: 2026-06-10

Financial Score16.0 / 40

News Sentiment19.4 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but the high debt ratio poses financial risk. Declined 14.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Jonggun Pharm is a major South Korean pharmaceutical company established in 1941, specializing in both prescription and over-the-counter drugs. It invests 9-11% of its sales in R&D, focusing on new drug development and biosimilars, with key products including the anticancer drug 'Camtovel' and the diabetes treatment 'Duvie'. As of 2023, it holds approximately 5% of the domestic pharmaceutical market share.

Number of Employees

2,304people

Average Salary

79.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.04Industry Average 11.933.0Point

Higher than industry avg (caution)

PBR

0.97Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

8.18Industry Average 4.017.0Point

2.0x industry avg (excellent)

Debt Ratio

27.61Industry Average 12.430.0Point

2.2x industry avg (risky)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼39.3% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 17.0% (declining, 3yr)

Detailed News Sentiment

20 totalPositive 16Neutral 3Negative 1Average Sentiment Score 77.8

Neutral
[혁신형 제약기업 점검]② 종근당, 3%대 마진에 커진 인증 셈법
종근당의 혁신형 제약기업 인증 재진입 준비에도 불구하고, 영업이익률이 낮아 수익성에 대한 우려가 제기됨.
Positive
종근당, 위식도 역류질환 치료제 ‘에소듀오미니’ 출시
종근당의 새로운 제형 축소 치료제 출시로 위식도 역류질환 환자들의 복용 편의성이 향상되어 긍정적 반응 예상.
Positive
종근당, 크기 줄인 위식도 역류질환 치료제 '에소듀오미니' 출시
종근당의 신약 '에소듀오미니' 출시로 제형 개선 및 효과 유지로 시장 경쟁력 강화.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 70,800Won52-week high 97,70052-week low 70,800

1-month return1.0Point

1m -14.80% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral기업지배구조보고서공시2026-06-01
Neutral주식등의대량보유상황보고서(약식)2026-06-01
Neutral분기보고서 (2026.03)2026-05-15
Neutral투자판단관련주요경영사항 (고혈압 치료제로 개발중인 CKD339의 식약처(MFDS) 제3상 임상시험 계획 승인 신청)2026-05-14